SCHEMBL8520855

SCHEMBL8520855

Cc1nc2c(C(=O)O)c(OCc3ccccc3)cc(CCc3ccccc3)n2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
FOLH1 Q04609 1/20 0.40
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
PTGER1 P34995 3/20 0.39
CYP1A2 P05177 1/20 0.39
SRD5A1 P18405 2/20 0.39
SRD5A2 P31213 2/20 0.39
P2RX3 P56373 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
BRD4 O60885 1/20 0.38
STAT3 P40763 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8520838 0.88 CYP2C9 (0.39) ALKBH1FFAR4PTGER1EGLN1BRD4
SCHEMBL8517219 0.73 PTGER1 (0.47) FFAR4FOLH1KDM5APTGER1SRD5A1
SCHEMBL26601663 0.68 MCL1 (0.51) ALKBH1FOLH1PTGER1MEN1KMT2A
SCHEMBL26608574 0.68 SMN1; SMN2 (0.53) FFAR4PTGER1MEN1KMT2ARXRA
SCHEMBL31518041 0.68 MCL1 (0.51) ALKBH1FOLH1PTGER1MEN1KMT2A
SCHEMBL31518023 0.68 SMN1; SMN2 (0.53) FFAR4PTGER1MEN1KMT2ARXRA
SCHEMBL31644031 0.68 MAPT (0.53) FFAR4FOLH1PTGER1MEN1KMT2A
SCHEMBL8520679 0.66 EGLN2 (0.43) FOLH1PTGER1MEN1KMT2AEGLN1
SCHEMBL15744035 0.66 PTGER1 (0.44) FFAR4PTGER1EGLN1BRD4SMN1; SMN2
SCHEMBL1842000 0.66 MEN1 (0.56) ALKBH1FFAR4FOLH1SRD5A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 US disclosed
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 US disclosed
EP-2455381-B1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-05-28 EP disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 US disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 US disclosed
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 US disclosed
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 US disclosed
EP-2455381-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER Japan Tobacco, Inc. (JP) 2012-05-23 EP disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 ALKBH1 1647/4885FFAR4 4684/4885FOLH1 1036/4885
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 ALKBH1 1647/4885FFAR4 4684/4885FOLH1 1036/4885
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 ALKBH1 1647/4885FFAR4 4684/4885FOLH1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.